Affiliation: University of Southern California
Huynh N, Arabian N, Asatryan L, Davies D. Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. J Vis Exp. 2019;: pubmed publisher
..The simple and high throughput nature of both of these paradigms allow for rapid screening of pharmacological agents or for identifying strains of mice that exhibit certain voluntary drinking behavior. ..
Naito A, Muchhala K, Asatryan L, Trudell J, Homanics G, Perkins D, et al
. Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research. Mol Pharmacol. 2014;86:635-46 pubmed publisher
..Collectively, our studies set the stage for using USER technology in genetically engineered animals as a unique tool to increase understanding of the neurobiological basis of the behavioral effects of ethanol. ..
Davies D, Bortolato M, Finn D, Ramaker M, Barak S, Ron D, et al
. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res. 2013;37:8-15 pubmed publisher
..This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs. ..
Naito A, Muchhala K, Trang J, Asatryan L, Trudell J, Homanics G, et al
. Manipulations of extracellular Loop 2 in Î±1 GlyR ultra-sensitive ethanol receptors (USERs) enhance receptor sensitivity to isoflurane, ethanol, and lidocaine, but not propofol. Neuroscience. 2015;297:68-77 pubmed publisher
..Collectively, these data indicate the commonality of the sites for isoflurane, lidocaine, and ethanol action, and the structural requirements for allosteric modulation on Î±1 GlyRs within the extracellular Loop 2 region. ..
Yardley M, Huynh N, Rodgers K, Alkana R, Davies D. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol. 2015;49:553-9 pubmed publisher
..Overall, these data support the use of this novel method of oral drug delivery for longer-term studies and should facilitate FDA required preclinical testing that is necessary to repurpose IVM for treatment of an AUD. ..
Khoja S, Huynh N, Warnecke A, Asatryan L, Jakowec M, Davies D. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl). 2018;235:1697-1709 pubmed publisher
..Taken together, these findings support the utility of avermectins as a novel class of drug candidates for treatment of AUDs. ..
Huynh N, Arabian N, Lieu D, Asatryan L, Davies D. Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals. J Vis Exp. 2016;:e53770 pubmed publisher
..Herein, we demonstrate that preclinical, oral drug delivery using the ODS method represents a safe, convenient, and humane alternative to oral gavage. ..
Huynh N, Arabian N, Naito A, Louie S, Jakowec M, Asatryan L, et al
. Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Neuropharmacology. 2017;113:60-70 pubmed publisher
..Overall, the results illustrate the potential for development of MOX as a novel pharmacotherapy for the treatment of AUD. ..
Khoja S, Huynh N, Asatryan L, Jakowec M, Davies D. Reduced expression of purinergic P2X4 receptors increases voluntary ethanol intake in C57BL/6J mice. Alcohol. 2018;68:63-70 pubmed publisher
..Collectively, the findings support the hypothesis that P2X4Rs play a role in regulation of ethanol intake and that P2X4Rs represent a novel drug target for treatment of alcohol use disorder. ..